Chronic Hepatitis C Infection: Basic Knowledges, Drugs and Therapeutic Guidelines

Main Article Content

Somwang Janyakhantikul

Abstract

Chronic hepatitis C virus infection is one of the main problems in public health as vaccine is not yet available for prevention the disease, and patients who do not receive therapy may experience cirrhosis and hepatocellular carcinoma. Drugs using in standard therapy (peginterferon-a and ribavirin) show different effects on individuals, and many patients have to discontinue the drugs due to their toxicities. Currently, a number of drugs in the new class of anti-hepatitis C virus (direct-acting antivirals; DAAs) have been developed and some are already approved by U.S. Food and Drug Administration and European Medicines Agency. This new class of drug has high efficacy. Therapeutic guidelines for chronic hepatitis C virus infection, therefore, have been changed. This article reviews the structure of hepatitis C virus, epidemiology, diagnosis and the goals of therapy, peginterferon-a and ribavirin treatment, factors that affect to therapeutic response (including pharmacogenetics in chronic hepatitis C virus infection), direct-acting antivirals and the update of therapeutic guidelines.

Downloads

Download data is not yet available.

Article Details

Section
Review Article

References

AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. [cited 2015 Sep 1] Available from: http://www.hcvguidelines.org.

Asselah T, Estrabaud E, Bieche I, et al. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 2010; 30(9):1259-1269.

Cariani E, Roli L, Missale G, et al. Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis. Pharmacogenomics J 2015.

Chevaliez S, Pawlotsky JM. HCV Genome and Life Cycle. In: Tan SL editor. Hepatitis C Viruses: Genomes and Molecular Biology. Norfolk (UK): Horizon Bioscience; 2006. 5-47.

Daklinza (daclatasvir). US FDA approved product information. [cited 2015 Sep 1]. Available from: http://packageinserts.bms.com/pi/pi_daklinza.pdf

European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 63(1): 199-236.

Exviera (Dasabuvir). European Medicines Agency approved product information. [cited 2015 Sep 1]. Available from:http://ec.europa.eu/health/documents/communityregister/2015/20150115130446anx_130446_en.pdf

Gao B, Hong F, Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 2004; 39(4):880-890.

Gatselis NK, Zachou K, Saitis A, et al. Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol 2014; 20(11): 2839-2853.

Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461(7262): 399-401.

Harvoni (ledipasvir/sofosbuvir). US FDA approved product information. [cited 2015 Sep 1]. Available from: https://www.gilead.com/~/media/Files/pdfs/medicines/liverdisease/harvoni/harvoni_pi.pdf

Honda M, Sakai A, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139(2): 499-509.

Jatapai A, Nelson KE, Chuenchitra T, et al. Prevalence and risk factors for hepatitis C virus on infection among Thai Men. Am J Trop Med Hyg 2010; 83(2): 433-439.

Jensen DM, Pol S. IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late? Liver Int 2012; 32 Suppl 1: 74-78.

Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, et al. Metaanalysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med 2013; 11:6.

Kalinina OV, Dmitriev AV. Structural and functional genome organization and life cycle of hepatitis C virus. Mol. Gen. Mikrobiol. Virusol 2015; 30(2): 64-70.

Kiser JJ, Flexner C. Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol 2013; 53: 427-449.

Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370(20): 1879-1888.

Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and

treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384 (9956): 1756-1765.

Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013; 368(20): 1907- 1917.

Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: effi cacy, side effects, and complications. Gut 2006; 55(9): 1350-1359.

Merck. Merck Voluntarily Discontinuing VICTRELIS (boceprevir) 200 mg Capsules. Dear Health Care Professional letter. January 2015.

Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015; 61(1): 77-87.

Muir AJ, Gong L, Johnson SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. Clin Pharmacol Ther 2014; 95(2): 141-146.

National Institutes of Health. NIH consensus statement on management of hepatitis C: 2002. NIH consensus and state-of-the-science statements. 2002; 19(3): 1-46.

Olysio (simeprevir). US FDA approved product information. [cited 2015 Sep 1]. Available from: https://www.olysio.com/shared/product/olysio/prescribing-information.pdf

Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology 2006; 43(2 Suppl 1): S207-S220.

Pineda-Tenor D, García-Álvarez M, Jiménez-Sousa MA, et al. Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis. J Transl Med 2015; 13(1): 320.

Pockros PJ. Direct-acting antivirals for the treatment of hepatitis C virus infection. UpToDate 2015 Aug [cited 2015 Sep 1]. Available from: http://www.uptodate.com/contents/direct-acting-antivirals-for-thetreatment-of-hepatitis-c-virus-infection

Proungvitaya T, Jantorn S, Suwannathada S, et al. Incidence of hepatitis B and C virus in new cases of hepatocellular carcinoma patients attending at National cancer institute. JMTPT 2012; 24(3): 264-271.

Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138(4): 1338-1345.

Sovaldi (sofosbuvir). US FDA approved product information. [cited 2015 Sep 1]. Available from:http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf

Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41(10):1100-1104.

Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139(5):1593-1601.

Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41(10):1105-1109.

Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, et al. Relationship between the HLA-B*1502 allele and carbamazepineinduced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol 2013; 149(9): 1025-1032.

Urban TJ, Thompson AJ, Bradrick SS, et al. IL28B genotype is associated with differential expression of intrahepatic interferonstimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52(6): 1888-1896.

Vertex Pharmaceuticals. Discontinuation of INCIVEK (telaprevir) tablets in the United States. Dear HealthCare Provider letter. August 11, 2014.

Viekirax (Ombitasvir/Paritaprevir/Ritonavir). European Medicines Agency approved product information. [cited 2015 Sep 1]. Available from: http://ec.europa.eu/health/documents/community-register/2015/20150115130406/anx_130406_en.pdf

Wasitthankasem R, Vongpunsawad S, Siripon N, et al. Genotypic distribution of hepatitis C virus in Thailand and Southeast Asia. PLoS One 2015; 10(5): e0126764.

Witte K, Witte E, Sabat R, Wolk K. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev 2010; 21(4): 237-251.

World Health Organization (WHO). Guidelines for the screening, care and treatment of persons with hepatitis C infection. 2014.